{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:06:33Z","timestamp":1771329993168,"version":"3.50.1"},"reference-count":42,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,11,21]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes of patients with T2D and CKD in China who initiated sodium-glucose cotransporter 2 inhibitors (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1 RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Demographic and clinical data of patients from a regional electronic health records database in Tianjin, China between 2012 and 2019 were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Adult patients diagnosed with T2D and CKD who initiated SGLT2i or GLP-1 RA from 2012 to 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Baseline demographic and disease characteristics, comorbidities and comedications, healthcare resource utilisation (HRU), and clinical outcomes were assessed using descriptive statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 935 and 4821 patients were included in SGLT2i and GLP-1 RA cohorts, with the mean ages of 59 and 56 years, respectively. Both cohorts had similar durations of T2D (mean: 5 years) and CKD (mean: 3 years). In SGLT2i and GLP-1 RA cohorts, 54.4% and 56.9% of patients had hemoglobin A1c (HbA1c) &gt;7%, and 50.5% and 54.1% were classified as CKD stage 1 at baseline. During the follow-up period (median 1.4 months for SGLT2i cohort and median 2.3 months for GLP-1 RA cohort), higher numbers of specialist visits compared with general practitioner visits were observed numerically for both cohorts. The incidence rates (95%\u2009CI) of kidney failure per 100 person-years were 3.1 (1.0, 7.3) for SGLT2i cohort, and 4.9 (3.9, 6.0) for GLP-1 RA cohort during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides descriptive evidence regarding the clinical characteristics and outcomes of patients with T2D and CKD who initiated SGLT2i or GLP-1 RA in China. The results are important for understanding the existing HRU and residual risk of severe clinical outcomes in such patient populations. The findings also provide a solid foundation for future research aimed at examining the clinical outcomes of new therapeutic options for T2D and CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-106126","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:10:42Z","timestamp":1771326642000},"page":"e106126","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and outcomes of patients with type 2 diabetes mellitus and chronic kidney disease from two new-user medication cohorts: a retrospective cohort study using regional electronic health records database in China"],"prefix":"10.1136","volume":"15","author":[{"given":"Xiaoqing","family":"Deng","sequence":"first","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Chen","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Xu","sequence":"additional","affiliation":[{"name":"Bayer Healthcare Company Ltd, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Wei","sequence":"additional","affiliation":[{"name":"Real-World Solutions, IQVIA Ltd, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Liao","sequence":"additional","affiliation":[{"name":"Bayer Healthcare Company Ltd, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Liu","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo E","family":"Farjat","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus G","family":"Oberprieler","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Chen","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"2026010307024366000_15.12.e106126.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843"},{"key":"2026010307024366000_15.12.e106126.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2015.173"},{"key":"2026010307024366000_15.12.e106126.3","article-title":"The Bidirectional Link Between Diabetes and Kidney Disease: Mechanisms and Management","volume":"15","author":"Kumar","year":"2023","journal-title":"Cureus"},{"key":"2026010307024366000_15.12.e106126.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.17379"},{"key":"2026010307024366000_15.12.e106126.5","doi-asserted-by":"crossref","DOI":"10.2196\/54429","article-title":"Prevalence and Risk Factors of Chronic Kidney Disease in Patients With Type 2 Diabetes in China: Cross-Sectional Study","volume":"10","author":"Shi","year":"2024","journal-title":"JMIR Public Health Surveill"},{"key":"2026010307024366000_15.12.e106126.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61350-6"},{"key":"2026010307024366000_15.12.e106126.7","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0027"},{"key":"2026010307024366000_15.12.e106126.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-020-01197-z","article-title":"Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis","volume":"20","author":"Yamada","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026010307024366000_15.12.e106126.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"2026010307024366000_15.12.e106126.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"2026010307024366000_15.12.e106126.11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022376","article-title":"Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure","volume":"11","author":"Htoo","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026010307024366000_15.12.e106126.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"2026010307024366000_15.12.e106126.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"2026010307024366000_15.12.e106126.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"2026010307024366000_15.12.e106126.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"2026010307024366000_15.12.e106126.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026010307024366000_15.12.e106126.17","doi-asserted-by":"publisher","DOI":"10.1016\/J.KINT.2023.10.018"},{"key":"2026010307024366000_15.12.e106126.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31150-X"},{"key":"2026010307024366000_15.12.e106126.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616011"},{"key":"2026010307024366000_15.12.e106126.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"2026010307024366000_15.12.e106126.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"2026010307024366000_15.12.e106126.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"2026010307024366000_15.12.e106126.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-024-02344-w","article-title":"FOUNTAIN: a modular research platform for integrated real-world evidence generation","volume":"24","author":"Oberprieler","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"2026010307024366000_15.12.e106126.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-023-17280-5","article-title":"Comparison of clinical characteristics and disease burden between early- and late-onset type 2 diabetes patients: a population-based cohort study","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Public Health"},{"key":"2026010307024366000_15.12.e106126.25","doi-asserted-by":"crossref","first-page":"1037564","DOI":"10.3389\/fendo.2022.1037564","article-title":"Naoxintong capsule delay the progression of diabetic kidney disease: A real-world cohort study","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026010307024366000_15.12.e106126.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2017.02.018"},{"key":"2026010307024366000_15.12.e106126.27","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.37765\/ajmc.2021.88660","article-title":"Targeted literature review of the burden of illness in patients with chronic kidney disease and type 2 diabetes","volume":"27","author":"Fried","year":"2021","journal-title":"Am J Manag Care"},{"key":"2026010307024366000_15.12.e106126.28","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/ndt\/gfac285","article-title":"Clinical implications and guidelines for CKD in type 2 diabetes","volume":"38","author":"Zhang","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026010307024366000_15.12.e106126.29","first-page":"455","article-title":"Expert consensus on clinical management for chronic kidney disease in diabetes mellitus in China","volume":"40","author":"Wang","year":"2024","journal-title":"Chin J Endocrinol Metab"},{"key":"2026010307024366000_15.12.e106126.30","first-page":"1394","article-title":"National technical guidelines for the prevention and treatment of diabetic kidney disease in primary care (2023)","volume":"62","year":"2023","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"2026010307024366000_15.12.e106126.31","first-page":"1506","article-title":"Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database","volume":"26","author":"Folkerts","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"2026010307024366000_15.12.e106126.32","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/ckj\/sfaa200","article-title":"Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study","volume":"14","author":"Kovesdy","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026010307024366000_15.12.e106126.33","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1093\/ckj\/sfac168","article-title":"Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort","volume":"15","author":"Pollock","year":"2022","journal-title":"Clin Kidney J"},{"key":"2026010307024366000_15.12.e106126.34","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0076","article-title":"Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study","volume":"12","author":"Vizcaya","year":"2023","journal-title":"J Comp Eff Res"},{"key":"2026010307024366000_15.12.e106126.35","unstructured":"General Office of the State Council of the People\u2019s Republic of China . Guidance from the general office of the state council on promoting the construction of the tiered medical system. 2015."},{"key":"2026010307024366000_15.12.e106126.36","unstructured":"General Office of Tianjin Municipal People\u2019s Government . Long-term plan for the prevention and treatment of chronic diseases in Tianjin (2017-2025). 2017."},{"key":"2026010307024366000_15.12.e106126.37","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101510","article-title":"Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis","volume":"50","author":"Lui","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2026010307024366000_15.12.e106126.38","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000664"},{"key":"2026010307024366000_15.12.e106126.39","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000040558","article-title":"Landscape of cardiorenal syndrome research: A bibliometric analysis","volume":"103","author":"Sun","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"2026010307024366000_15.12.e106126.40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.067584"},{"key":"2026010307024366000_15.12.e106126.41","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026010307024366000_15.12.e106126.42","unstructured":"WHO . Obesity and overweight. 2024. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-106126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:10:46Z","timestamp":1771326646000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-106126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,24]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjopen-2025-106126"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-106126","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}